PHARMACYTE BIOTECH, INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
PHARMACYTE BIOTECH, INC. (PMCB) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $28.26 million as of 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-07-29
- 2026-04-30: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $28.26M.
- 2025-04-30: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $30.92M.
- 2024-04-30: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $27.00M.
- 2024-01-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $49.92M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2026-04-30 | $28.26M 10-K · filed 2026-07-29 | |
| 2025-04-30 | $30.92M 10-K · filed 2025-08-11 | |
| 2024-04-30 | $27.00M 10-K · filed 2024-08-13 | |
| 2024-01-31 | $49.92M 10-Q · filed 2024-03-18 | |
| 2023-10-31 | $48.95M 10-Q · filed 2023-12-15 | |
| 2023-07-31 | $50.75M 10-Q · filed 2023-09-18 | |
| 2023-01-31 | $52.19M 10-Q · filed 2023-03-16 | |
| 2022-10-31 | $52.08M 10-Q · filed 2022-12-14 | |
| 2022-07-31 | $50.12M 10-Q · filed 2022-09-14 | |
| 2022-04-30 | $36.42M 10-K · filed 2026-07-29 | $48.62M 10-K · filed 2022-07-28 |
| 2021-04-30 | $44.16M 10-K · filed 2021-08-10 | |
| 2020-04-30 | $41.20M 10-K · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |